DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE
- Product Name
- DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE
- CAS No.
- 108147-54-2
- Chemical Name
- DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE
- Synonyms
- MIGALASTAT;(2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol;DGJ;Migalasta;GALACTOSTATIN HCL;DGJ, HYDROCHLORIDE;1-Deoxygalactonojirimycin;DEOXYGALACTONOJIRIMYCIN HCL;1-DEOXYGALACTONOJIRIMYCIN HCL;1,5-dideoxy-1,5-iminogalactitol
- CBNumber
- CB2252940
- Molecular Formula
- C6H13NO4
- Formula Weight
- 163.17
- MOL File
- 108147-54-2.mol
DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE Property
- Melting point:
- 243-245 °C
- Boiling point:
- 361.1±42.0 °C(Predicted)
- Density
- 1.456±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- pka
- 13.77±0.70(Predicted)
N-Bromosuccinimide Price
- Product number
- 293236
- Product name
- 1-Deoxygalactonojirimycin
- Packaging
- 10g
- Price
- $36136
- Updated
- 2021/12/16
- Product number
- 8856
- Product name
- Deoxygalactonojirimycin, Hydrochloride
- Packaging
- 1mg
- Price
- $90
- Updated
- 2021/12/16
- Product number
- API0008119
- Product name
- MIGALASTAT
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $499.83
- Updated
- 2021/12/16
DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE Chemical Properties,Usage,Production
Uses
Migalastat (GR181413A free base) is an orally active α-galactosidase A molecular chaperone, with an IC50 value of 0.04 μM for human α-Gal A. Migalastat binds to the active site of certain unstable mutant forms of α-galactosidase A, facilitating their transport to the lysosome. After dissociation in the acidic environment, Migalastat enables the mutant α-galactosidase A to exhibit biological activity[1].
Definition
ChEBI: Migalastat is a member of piperidines.
brand name
Treatment of Fabry disease.
in vivo
Fabry disease is an X-linked recessive disorder caused by the deficient activity of α-galactosidase A[2].
Migalastat (oral gavage, 3 mg/kg daily for 4 weeks) increases α-Gal A activity in heart, kidney, spleen, and liver in a dose- and time-dependently in transgenic mice that express human mutant alpha-Gal A (TgM)[2].
Migalastat shows the half-life of less than 1 day in all major issues in TgM for 2 weeks pretreatment[2].
Migalastat (oral gavage, 100 mg/kg daily for 28 days) to transgenic mice reduces lyso-Gb3 levels up to 64%, 59%, and 81% in kidney, heart, and skin, respectively[3].
| Animal Model: | Male nontransgenic (Non-Tg) C57BL/6 mice; transgenic mice expressing human mutant R301Q α-Gal A (TgM), α-Gal A knockout mice (KO), mice express human R301Q α-Gal A in a null background (TgM/KO)[2] |
| Dosage: | 3 mg/kg |
| Administration: | Oral gavage; every day for 4 weeks |
| Result: | Reduced Globotriaosylceramide (Gb3) storage remarkably in kidney of mice. |
References
[1] Asano N, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000 Jul;267(13):4179-86. DOI:10.1046/j.1432-1327.2000.01457.x
[2] Ishii S, et al. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J Pharmacol Exp Ther. 2009 Mar;328(3):723-31. DOI:10.1124/jpet.108.149054
[3] Young-Gqamana B, et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One. 2013;8(3):e57631. DOI:10.1371/journal.pone.0057631
[4] Welford RWD, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018 Oct. 27(19):3392-3403. DOI:10.1093/hmg/ddy248
DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE Preparation Products And Raw materials
Raw materials
Preparation Products
DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE Suppliers
View Lastest Price from DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE manufacturers
- Product
- DEOXYGALACTONOJIRIMYCIN, HYDROCHLORIDE 108147-54-2
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 98
- Supply Ability
- 200kg
- Release date
- 2019-09-10